Cann Group Ltd. · ASX:CAN
Cann — Investor Presentation (October 2025)
30 slides from Cann's investor presentation, Oct 27, 2025
Slide 1: Cann Group Limited Capital Raising Presentation
ASX:CAN CANN GROUP LIMITED Capital Raising Presentation At the forefront of medicinal cannabis in Australia since 2017 October 2025 Not for release to US wire services or distribution in the United States
Slide 2: Important notice and disclaimer
Disclaimer Important notice and disclaimer The following important notice and disclaimer applies to this presentation and you are therefore advised to read this carefully before making any use of this presentation or any information contained within it. This presentation has been prepared by Cann Gr
Slide 3: Disclaimer (cont.)
Disclaimer (cont.) Non-IFRS measures You should also be aware that certain financial measures included in this presentation are ‘non-IFRS financial information’ under ASIC Regulatory Guide 230: ‘Disclosing non-IFRS financial information’ published by ASIC and also ‘non-GAAP financial measures’ withi
Slide 4: Executive Summary
Executive Summary Cann Group set to fast-track future growth by leveraging capital to cut debt and unlock higher margins • Founded 2014; ASX-listed (ASX:CAN) since 2017 • First Australian company licensed to research and cultivate medicinal cannabis Company overview • HQ in Melbourne; flagship Mildu
Slide 5: Refinance & Equity Raise
Refinance & Equity Raise 81% debt reduction contributes $61M of net assets and ~$3.4M interest savings p/a – positioning Cann for EBITDA positive FY2026 and beyond. Capital Raising Presentation — October 2025
Slide 6: Recapitalisation Overview
Recapitalisation Overview Significant debt reduction and recapitalisation position the company for EBITDA-positive FY26 and sustained long-term growth Debt restructure overview Debt Pre and Post Refinance $m $75.4m +$9.0m -$15.3m -$54.6m =$14.5m core debt $75.4 new debt NAB debt NAB debt debt post a
Slide 7: Company Overview
Company Overview Cann Group is arguably the largest producer of medicinal cannabis dried flower in Australia via its state-of-the-art GMP production facility in the Sunraysia region, Victoria. Capital Raising Presentation — October 2025
Slide 8: Best-in-class Glasshouse and GMP Production Facility
Best-in-class Glasshouse and GMP Production Facility One of Australia’s largest, high-tech, indoor glasshouse cannabis production facilities State-of-the-art indoor glasshouse facility specifications Features and capability Microclimate-controlled glasshouse (architected by well-known Van PRIVA
Slide 9: Board and Senior Management
Board and Senior Management Experienced leadership with global agri, pharma and finance expertise Jenni Pilcher Michael Long CEO & Managing Director VP Operations and Strategic Partnerships Jenni has almost 20 years of senior finance executive experience in the medical, biotechnology Michael has ext
Slide 10: Investment Highlights
Investment Highlights Strategic platform built for sustainable, profitable growth Sales revenue forecast to grow ~50% Gross Margins rising > 50% through to ~$17m and EBITDA of $0.3m - a 35% operating expense reduction $0.7m in FY26 (first positive EBITDA in FY25 month in Aug-25) Cann’s own brand “Bo
Slide 11: Global Market Overview
Global Market Overview Global medicinal cannabis market expanding with North American leaders showing substantial share price growth Europe 30% global USA / Canada Cannabis Index vs Aus Cannabis Global Market projected to Index rise from US$44.6B in 2025 demand - strong growth North America dominate
Slide 12: Australian Market Overview
Australian Market Overview Fast-growing $500m+ market with untapped local supply potential Delivery Formats-Units Sold Strong Patient Growth – Scaling Industry Output – The 3,500,000 Australian medicinal cannabis Australian market valued at regulated medicinal cannabis users grew at ~11% CAGR from $
Slide 13: Industry Tailwinds
Industry Tailwinds Favourable regulation and global demand set stage for growth Units Sold vs Top 50 Products Market Share Rising Export Demand – European and other 4,000,000 70% Supportive Regulatory Shift – Ongoing international markets are increasingly reliant legal reforms and improving public o
Slide 14: Commercial Strategy
Commercial Strategy Expanding sales channels & entering new export markets White-Label Products Branded Products Dried flower supplied under customer branding Botanitech : Flower, oils, vapes, gummies, multiple THC/CBD SKUs Appeal: Lower-cost entry point for new customers New Brand Launch (Q
Slide 15: Commercial Strategy
Commercial Strategy Expanding sales channels & entering new export markets Immediate Near-Term Commercial Initiatives Chemist Warehouse Partnership New SKU’s for Botanitech Botanitech partnership with Chemist Warehouse has validated the brand 2 x Edible Gummies SKU’s launched this month. visibil
Slide 16: Product Suite – Botanitech
Product Suite – BotanitechTM Australian Innovation. Grown With Care. INC “It’s Not Curated & VAL Flower NRG Flower Oils Flower “Skylark" Craft” Flower Vape Carts Gummies Range Range Range March 2022 June 2023 January 2024 May 2024 August 2024 June 2025 October 2025 Capital Raising Presentation — Sep
Slide 17: R&D - Specialised Expertise and Know-how
R&D - Specialised Expertise and Know-how Australia’s Pioneer in Medicinal Cannabis Research & Cultivation Top 8 of Cann’s breeding candidates, developed in Top 3 from Cann’s breeder-pack seed importation program from collaboration with Ag-VIC as part of the “CRADA” program, North America have now en
Slide 18: Strategic Plan
Strategic Plan 3-phase plan launched March 2024 to secure financial stability and maximise stakeholder value COMPLETED 1-3 COMPLETED COMMENCE 2026 4 UNDERWAY Phase I Phase II Phase III Right-sizing | Secure funding Move toward break-even | Profitability | Retire Debt 2024 Refinance debt 2026 2025 1.
Slide 19: Cost Reduction and Margin Expansion
Cost Reduction and Margin Expansion Reduced operating costs driving strong double-digit margin growth Expenses vs Production (Dried Flower Trimmed Weight Mt) Total operating expenses reduced by 35% YoY1, driven 9.0 40,000,000 by a disciplined and ongoing efficiency program 8.0 Lower production c
Slide 20: FY25 Highlights
FY25 Highlights Strong start to FY26 underpinned by FY25 creating the strategic platform to becoming cash generating in the future Financial Performance FY22 to FY26(b) Dried flower production increased by 35% YOY to 5.9 tonne, 20 with annual run-rate at 9.2 tonne 15 Revenues from leading product (B
Slide 21: Outlook
Revenue Growth – Forecast Margin Expansion – Expected Debt Reduction – Core debt revenue of ~$17m in FY26, ~50% improvement in gross margin as reduced by ~80% to $14.5m, growth, underpinned by strong plant yields increase, cost per gram significantly strengthening the demand for bulk flower and fall
Slide 22: Appendices
Appendices Capital Raising Presentation — October 2025
Slide 23: Capital Raising Overview
Capital Raising Overview Capital raising of up to $9m via a two-tranche placement and SPP • Cann Group is undertaking a capital raise of up to approximately $9.0 million comprising: • A two-tranche institutional placement (“Placement”) to raise up to approximately $6.5 million Offer size and structu
Slide 24: Indicative Raise Timetable
Indicative Raise Timetable Event Date (AEDT)^ SPP record date Friday, 24 October 2025 Announcement of capital raising and Notice of Annual General Meeting circulated Monday, 27 October 2025 Settlement of tranche One Placement New Shares and SPP opens Thursday, 30 October 2025 Allotment and normal tr
Slide 25: Pro Forma Balance Sheet
Pro Forma Balance Sheet Interest Accrued Debt Equity Raise 30-Jun-25 RD Tax Refund Pro Forma to 30 September Restructure (net of costs) Current assets A$’000 A$’000 A$’000 A$’000 A$’000 A$’000 Cash and cash equivalents 10 545 (6,590) 8,460 2,440 Trade and other receivables 2,757 (1,766) 991 +$61.1M
Slide 26: Specific risk factors
Specific risk factors Agricultural risks: Risks inherent with agricultural businesses apply to Cann’s business, including lower than expected yields, disease, mould and insects and other pests. Production risks: Cann’s ability to produce cannabis and manufacture cannabis products, and to increase it
Slide 27: Specific risk factors
Specific risk factors Compliance with licence conditions: A licence to cultivate, produce and/or manufacture under the Narcotic Drugs Act 1967 (Cth) is subject to a number of conditions, which if not maintained may result in a suspension or revocation of the licence or permit. Such conditions includ
Slide 28: General risk factors
General risk factors The Company is also exposed to general risks, including (but not limited to) the following: Nature of investment: There are inherent risks associated with investment in any listed company. The New Shares under the Offer do not guarantee payment of dividends, return on capital or
Slide 29: International Offer Restrictions
International Offer Restrictions This presentation does not constitute an offer of New Shares or New Options of the Company in any jurisdiction in which it would be unlawful. In particular, this presentation may not be distributed to any person, and the New Shares and New Options may not be offered
Slide 30: Thank you
Thank you Jenni Pilcher CEO & Managing Director Jenni.pilcher@canngrouplimited.com Capital Raising Presentation — October 2025